Disclosed are a near-infrared absorbing composition, an optical structure, and a camera module and an electronic device including the same. The near-infrared absorbing composition includes a copper complex represented by Chemical Formula 1. ##STR00001##
Definitions of Chemical Formula 1 are the same as described in the detailed description.

Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.

The present invention pertains to the technical field of biomedicine, and relates to isopaucifloral F phosphate compounds and pharmaceutical uses thereof. It has been confirmed through experiments that said isopaucifloral F phosphate compounds and pharmaceutically acceptable salts thereof have effects on the bone remodeling process by exerting their anti-osteoporosis efficacy through a dual-mode mechanism of action of promoting osteogenesis and reducing osteoclast resorption, have the characteristics of high bioavailability, stable metabolism and good safety, and can be used to prepare a new generation of anti-osteoporosis drugs.

##STR00001##

The present invention relates to a non-aqueous electrolyte for a lithium secondary battery and a lithium secondary battery comprising same. The non-aqueous electrolyte comprises: a non-aqueous organic solvent; a lithium salt; a first additive containing at least one compound among compounds represented by chemical formulas 1 to 4; and a second additive containing at least one compound among compounds represented by chemical formula 5 or 6.

This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

This application provides a secondary battery and a device comprising the same. The secondary battery includes a negative electrode plate and an electrolyte. The negative electrode plate includes a negative electrode active material. The electrolyte includes an electrolyte salt, an organic solvent, and an additive. The negative electrode active material includes a silicon-based material. The organic solvent includes ethylene carbonate (EC) and diethyl carbonate (DEC). A mass ratio of EC in the organic solvent is less than or equal to 20%, and a mass ratio of DEC in the organic solvent is less than or equal to 20%. The additive includes an additive A and an additive B. The additive A is selected from one or more of compounds represented by Formula 1 or Formula 2, and the additive B is selected from one or more of compounds represented by Formula 3, as described in the application.

Disclosed is a continuous industrial production method of high-purity bisphenol A-bis(diphenyl phosphate). The method includes: dividing bisphenol A into two parts, mixing a part of the bisphenol A with phosphorus oxychloride and a Lewis acid catalyst, adding the mixture into a continuous multistage crosslinked reactor, removing excessive phosphorus oxychloride through distillation, adding an organic base acid binding agent and the rest of the bisphenol A to react for 1.5 to 3 h at a temperature of 115° C. to 120° C. to obtain an intermediate product reaction liquid, mixing the intermediate product reaction liquid with phenol, adding the mixture into a multistage esterification reactor for esterification reaction, continuously supplying the consumed phenol in the esterification process, obtaining a crude product after the reaction is completed, sequentially performing continuous acid washing, continuous alkali washing and continuous water washing, and performing continuous solvent recovery and filtration to obtain a bisphenol A-bis(diphenyl phosphate) finished product.

A compound represented by the following formula (1):

##STR00001##

wherein R.sup.101 to R.sup.103, each independently, are a C1-C6 organic group, optionally contain at least one selected from the group consisting of a hetero atom and an unsaturated bond, and are optionally linear, branched, or cyclic. Also disclosed is an electrolyte solution containing the compound, an electrochemical device containing the electrolyte solution, a lithium ion secondary battery containing the electrolyte solution and a module including the electrochemical device or the lithium ion secondary battery.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.